Develops drugs for lung diseases and rare genetic disorders.
Jun 2026Revenue $1.14B/yrExpenses $1.98B/yr
No trendCash runway ≈ 1.4 years from Jun 2026
Figures by year
When will INSMED be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.14B and expenses $1.98B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $606M | $1.85B | −$1.25B |
| Dec 2024 | $364M | $1.24B | −$878M |
| Dec 2023 | $305M | $1.01B | −$710M |
| Dec 2022 | $245M | $703M | −$457M |
| Dec 2021 | $188M | $564M | −$375M |
| Dec 2020 | $164M | $430M | −$265M |
| Dec 2019 | $136M | $372M | −$235M |
| Dec 2018 | $9.84M | $317M | −$307M |
| Dec 2017 | $0.00 | $189M | −$189M |
| Dec 2016 | $0.00 | $173M | −$173M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.